First Light Asset Management LLC Makes New Investment in GeneDx Holdings Corp. $WGS

First Light Asset Management LLC acquired a new stake in GeneDx Holdings Corp. (NASDAQ:WGS) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 242,927 shares of the company’s stock, valued at approximately $15,601,000. GeneDx accounts for approximately 1.4% of First Light Asset Management LLC’s investment portfolio, making the stock its 26th biggest position.

Other large investors have also recently made changes to their positions in the company. Lazard Asset Management LLC purchased a new position in shares of GeneDx in the 1st quarter worth about $2,177,000. Granahan Investment Management LLC increased its holdings in GeneDx by 212.5% during the first quarter. Granahan Investment Management LLC now owns 96,605 shares of the company’s stock worth $6,204,000 after buying an additional 65,695 shares during the last quarter. Renaissance Technologies LLC raised its position in GeneDx by 168.2% in the first quarter. Renaissance Technologies LLC now owns 153,716 shares of the company’s stock worth $9,872,000 after acquiring an additional 96,400 shares during the period. Keebeck Wealth Management raised its position in GeneDx by 13.5% in the first quarter. Keebeck Wealth Management now owns 4,310 shares of the company’s stock worth $277,000 after acquiring an additional 513 shares during the period. Finally, Cetera Investment Advisers boosted its stake in GeneDx by 16.6% in the first quarter. Cetera Investment Advisers now owns 3,616 shares of the company’s stock valued at $232,000 after acquiring an additional 516 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

GeneDx News Summary

Here are the key news stories impacting GeneDx this week:

• Neutral Sentiment: Multiple law firms reiterated that a securities class action has been filed against GeneDx and certain executives, with the case centered on alleged misstatements about the Fabric Genomics acquisition and related synergies. Article: WGS DEADLINE ALERT: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit- August 3, 2026 Deadline
• Negative Sentiment: Several firms highlighted that investors have until August 3, 2026 to seek lead-plaintiff status, keeping the lawsuit in focus and potentially increasing overhang on the stock. Article: WGS 10-DAY DEADLINE ALERT: GeneDx Holdings Corp. (NASDAQ: WGS) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, August 3, 2026 Lead Plaintiff Deadline
• Negative Sentiment: Attorney promotions and investor alerts also pointed to the sharp stock selloff after GeneDx’s May earnings update, which disclosed a large impairment charge and weaker guidance, reinforcing concerns about prior disclosures and fundamentals. Article: Lost Money on GeneDx Holdings Corp. (WGS)? Join Class Action Suit Seeking Recovery – Contact SueWallSt

GeneDx Price Performance

GeneDx stock opened at $59.10 on Monday. The firm has a market capitalization of $1.75 billion, a P/E ratio of -22.05 and a beta of 1.90. GeneDx Holdings Corp. has a one year low of $32.21 and a one year high of $170.87. The company has a debt-to-equity ratio of 0.38, a current ratio of 3.09 and a quick ratio of 2.95. The business has a fifty day moving average price of $58.75 and a 200-day moving average price of $72.02.

GeneDx (NASDAQ:WGS) last released its quarterly earnings data on Monday, May 4th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.22). The company had revenue of $102.25 million for the quarter, compared to the consensus estimate of $112.46 million. GeneDx had a negative net margin of 17.58% and a positive return on equity of 9.15%. During the same quarter in the previous year, the firm posted ($0.23) earnings per share. As a group, equities research analysts forecast that GeneDx Holdings Corp. will post -1 EPS for the current year.

Insider Transactions at GeneDx

In related news, Director Casdin Capital, Llc purchased 185,000 shares of the firm’s stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average cost of $42.60 per share, for a total transaction of $7,881,000.00. Following the completion of the transaction, the director directly owned 3,367,164 shares in the company, valued at approximately $143,441,186.40. This represents a 5.81% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Keith A. Meister purchased 533,758 shares of the stock in a transaction dated Thursday, May 7th. The stock was purchased at an average cost of $37.86 per share, for a total transaction of $20,208,077.88. Following the completion of the acquisition, the director owned 3,761,908 shares of the company’s stock, valued at approximately $142,425,836.88. This represents a 16.53% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last ninety days, insiders have acquired 2,256,420 shares of company stock valued at $93,144,340 and have sold 21,699 shares valued at $1,295,646. 25.17% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have recently issued reports on WGS. BTIG Research decreased their price target on shares of GeneDx from $170.00 to $90.00 and set a “buy” rating for the company in a research note on Tuesday, May 5th. Craig Hallum reaffirmed a “buy” rating and set a $85.00 price target on shares of GeneDx in a research report on Tuesday, May 5th. Weiss Ratings downgraded GeneDx from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, June 1st. Zacks Research cut GeneDx from a “hold” rating to a “strong sell” rating in a research note on Monday, June 29th. Finally, Wells Fargo & Company reaffirmed an “overweight” rating and set a $75.00 price objective (down from $155.00) on shares of GeneDx in a report on Tuesday, May 5th. Seven research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $87.43.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.